[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2132135T3 - Procedimiento para la preparacion de compuestos de tiazolidina u oxazolidina farmaceuticamente activos mediante una reductasa de levadura. - Google Patents

Procedimiento para la preparacion de compuestos de tiazolidina u oxazolidina farmaceuticamente activos mediante una reductasa de levadura.

Info

Publication number
ES2132135T3
ES2132135T3 ES92923876T ES92923876T ES2132135T3 ES 2132135 T3 ES2132135 T3 ES 2132135T3 ES 92923876 T ES92923876 T ES 92923876T ES 92923876 T ES92923876 T ES 92923876T ES 2132135 T3 ES2132135 T3 ES 2132135T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
formula
pharmaceutically active
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92923876T
Other languages
English (en)
Inventor
Richard M Smithkline B Hindley
Stefan Roland Woroniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2132135T3 publication Critical patent/ES2132135T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN PROCESO PARA PREPARAR UN COMPUESTO DE FORMULA (I), O UNA FORMA TAUTOMERICA DE LA MISMA Y/O SAL DE LA MISMA FARMACEUTICAMENTE ACEPTABLE Y/O UN SOLVATO DE LA MISMA FARMACEUTICAMENTE ACEPTABLE, EN EL QUE: T REPRESENTA UN GRUPO ARILO SUSTITUIDO O NO SUSTITUIDO Y T1 IS O O S; CUYO PROCESO COMPRENDE EL TRATAMIENTO DE UN COMPUESTO DE FORMULA (II), O FORMA TAUTOMERICA DE LA MISMA Y/O UNA SAL DE LA MISMA Y/O UN SOLVATO DE LA MISMA, DONDE T Y T1 SON CONFORME A LO DEFINIDO EN RELACION CON LA FORMULA (I), CON UNA REDUCTASA MICROBIAL OBTENIDA DE UNA LEVADURA ROJA ADECUADA; Y DESPUES, CONFORME SE REQUIERA, PREPARAR UNA SAL FARMACEUTICAMENTE ACEPTABLE Y/O UN SOLVATO FARMACEUTICAMENTE ACEPTABLE DEL COMPUESTO DE FORMULA (I), O UNA FORMA TAUTOMERICA DE LA MISMA; COMPUESTOS PREPARADOS MEDIANTE TAL CLASE DE PROCESO Y EL USO DE TALES COMPUESTOS EN MEDICINA.
ES92923876T 1991-11-19 1992-11-19 Procedimiento para la preparacion de compuestos de tiazolidina u oxazolidina farmaceuticamente activos mediante una reductasa de levadura. Expired - Lifetime ES2132135T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919124513A GB9124513D0 (en) 1991-11-19 1991-11-19 Novel process

Publications (1)

Publication Number Publication Date
ES2132135T3 true ES2132135T3 (es) 1999-08-16

Family

ID=10704843

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92923876T Expired - Lifetime ES2132135T3 (es) 1991-11-19 1992-11-19 Procedimiento para la preparacion de compuestos de tiazolidina u oxazolidina farmaceuticamente activos mediante una reductasa de levadura.

Country Status (19)

Country Link
US (2) US5726055A (es)
EP (2) EP0615549B1 (es)
JP (1) JP3782099B2 (es)
KR (2) KR100270133B1 (es)
AT (1) ATE181114T1 (es)
AU (3) AU673145B2 (es)
CA (1) CA2123782A1 (es)
DE (1) DE69229402T2 (es)
DK (1) DK0615549T3 (es)
ES (1) ES2132135T3 (es)
GB (1) GB9124513D0 (es)
GR (1) GR3031029T3 (es)
HK (1) HK1012423A1 (es)
MX (1) MX9206679A (es)
NZ (1) NZ245182A (es)
PT (1) PT101077B (es)
TW (1) TW240249B (es)
WO (1) WO1993010254A1 (es)
ZA (1) ZA928937B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
ATE325607T1 (de) * 1997-11-19 2006-06-15 Takeda Pharmaceutical Aptoptoseinhibitoren
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
WO2000064896A1 (en) 1999-04-23 2000-11-02 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
AR023564A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Plc Una forma polimorfica de sal del acido maleico derivado del tiazolidina-2,4 diona, una composicion farmaceutica y el uso del mismo para la fabricacion deun medicamento
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
EP1291436A1 (en) * 2001-09-11 2003-03-12 Bayer Ag Process for the stereoselective preparation of functionalized vicinal diols
CZ297347B6 (cs) * 2004-09-21 2006-11-15 Zentiva, A. S. Zpusob prípravy rosiglitazonu
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE3001303A1 (de) * 1980-01-16 1981-07-23 Basf Ag, 6700 Ludwigshafen Optisch aktive phenylpropan-derivate, ihre herstellung und verwendung
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK173350B1 (da) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
US4857468A (en) * 1985-04-13 1989-08-15 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing optically active 2-halo-1-phenyl ethanol
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use

Also Published As

Publication number Publication date
ZA928937B (en) 1994-03-17
GB9124513D0 (en) 1992-01-08
JP3782099B2 (ja) 2006-06-07
PT101077A (pt) 1994-02-28
DE69229402D1 (de) 1999-07-15
DE69229402T2 (de) 1999-11-25
KR100270133B1 (ko) 2000-10-16
AU2949492A (en) 1993-06-15
DK0615549T3 (da) 1999-11-15
AU6572896A (en) 1996-12-12
HK1012423A1 (en) 1999-07-30
US5726055A (en) 1998-03-10
MX9206679A (es) 1993-05-01
JPH07503129A (ja) 1995-04-06
ATE181114T1 (de) 1999-06-15
EP0905255A3 (en) 1999-04-14
EP0905255A2 (en) 1999-03-31
WO1993010254A1 (en) 1993-05-27
AU673145B2 (en) 1996-10-31
US20020106762A1 (en) 2002-08-08
EP0615549A1 (en) 1994-09-21
AU8954098A (en) 1999-01-14
EP0615549B1 (en) 1999-06-09
NZ245182A (en) 1995-09-26
PT101077B (pt) 2000-09-29
KR20070108290A (ko) 2007-11-09
CA2123782A1 (en) 1993-05-27
TW240249B (es) 1995-02-11
GR3031029T3 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
ES2132135T3 (es) Procedimiento para la preparacion de compuestos de tiazolidina u oxazolidina farmaceuticamente activos mediante una reductasa de levadura.
AU560179B2 (en) Hypoglycemic thiazolidinedione derivatives
NO900306D0 (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
AT384424B (de) Verfahren zur herstellung von neuen 3-hydroxy-2-oxo-pyrrolidinderivaten und ihren salzen
NO161564C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-carbolin-3-oxadiazolylderivater.
ATE92489T1 (de) Imid-derivate, ihre herstellung und verwendung.
EP0270093A3 (en) Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties
AU632877B2 (en) Oxetane derivatives, their preparation and their use as anti-fungal or fungicidal agents
SE8107524L (sv) Heterocykliska foreningar
ATE171704T1 (de) Optisch wirksame alkylendioxybenzolderivate und ihre verwendung als arzneimittel
DE3677857D1 (de) 2,5-dimethylpyrrolderivative, ihre herstellung und ihre verwendung.
ATE100439T1 (de) 2-(2-hydroxy-3-phenoxypropylamino)-ethoxybenzol derivate.
CA2092919A1 (en) Epoxysuccinamic acid derivatives
DE3854205D1 (de) Zwischenprodukte der Mureidomycin-Gruppe, ihre Herstellung und Verwendung.
EP0449011A3 (en) Stereoselective process for the preparation of 2-amino-ethanol derivatives having a central analgesic activity and intermediates thereof
ATE109454T1 (de) Catecholaminester.
GB1469410A (en) Benzodioxole derivatives
DE69008431D1 (de) Verfahren zur Herstellung von Imidazol-Derivaten.
AU2874989A (en) Agent for animal growth promotion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 615549

Country of ref document: ES